Cartography, Gilead collaborate to develop therapies for breast and lung cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cartography Biosciences Inc. has entered a strategic collaboration agreement with Gilead Sciences Inc., to discover and develop therapies for patients with triple-negative breast cancer and the most common form of non-small cell lung cancer, adenocarcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

A recent OncoHost study provides insight in understanding resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer. Through a comprehensive bioinformatic analysis of pretreatment plasma proteomic profiles from 272 NSCLC patients, researchers identified key biological processes associated with resistance and revealed therapeutic targets that could inform future precision treatment strategies.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login